HUNGARIAN EXPERIENCES WITH LEVODOPA/CARBIDOPA INTESTINAL GEL IN THE TREATMENT OF ADVANCED PARKINSON'S DISEASE

被引:0
|
作者
Nagy, Helga [1 ,2 ]
Takats, Annannaria [1 ]
Toth, Adrian [1 ]
Bereczki, Daniel [1 ]
Klivenyi, Peter [3 ]
Dezsi, Livia [3 ]
Dibo, Gyoergy [3 ]
Vecsei, Laszlo [3 ,4 ]
Kovacs, Norbert [5 ]
Aschermann, Zsuzsa [5 ]
Komoly, Samue, I [5 ]
Varannai, Lajos [6 ]
Zemlenyi, Gyoengyi [6 ]
Valikovics, Attila [6 ]
机构
[1] Semmelweis Egyet, Neurol Klin, H-1083 Budapest, Hungary
[2] Orszagos Orvosi Rehabil Int, Budapest, Hungary
[3] Szegedi Tudomonyegyetem, Neurol Klin, Szeged, Hungary
[4] MTA SZTE, Szeged, Hungary
[5] Pecsi Tudomanyegyetem, Neurol Klin, Pecs, Hungary
[6] Borsod Abauj Zemplen Megyei Korhoz, Neurol Osztoly, Miskolc, Hungary
来源
IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE | 2014年 / 67卷 / 11-12期
关键词
advanced Parkinson's disease; motor and non - motor fluctuations; disturbing dyskinesias; effectiveness of LCIG therapy; results in Hungary; DUODENAL LEVODOPA INFUSION; CONTINUOUS DOPAMINERGIC STIMULATION; CONTINUOUS DRUG-DELIVERY; INTRAJEJUNAL LEVODOPA; NONMOTOR SYMPTOMS; MOTOR; EFFICACY; MULTICENTER; SAFETY;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
In the advanced Parkison's disease (PD) the late complications of levodopa therapy have to be considered: motor and/or non-motor fluctuations with or without disturbing dyskinesias. The non-motor fluctuations often influence the quality of life (QoL) in a much more negative way compared with the motor symptoms. In the treatment of advanced PD there are several device-aided methods - deep brain stimulation, apomorphine pump, levodopa/carbidopa intestinal gel (LCIG) - to improve the symptoms, the QoL, sometimes even in an individual, tailored custom form. The LCIG therapy was introduced in Hungary in 2011. Here we summarize the data of our patients: we have tested almost 60 patients and in 43 cases we have started this treatment. We analyze the duration of illness, levodopa therapy, motor and non-motor fluctuation of patients and present our experiences with the test phase and the chronic LCIG therapy via PEG/PEJ implantation. We paid attention to the surgery and device - depending side effects. Our experiences are similar to the international data. In patients selection "the right treatment, to the right patient, in the right time" is of importance.
引用
收藏
页码:385 / 389
页数:5
相关论文
共 50 条
  • [21] Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection
    Abbruzzese, Giovanni
    Barone, Paolo
    Bonuccelli, Ubaldo
    Lopiano, Leonardo
    Antonini, Angelo
    FUNCTIONAL NEUROLOGY, 2012, 27 (03) : 147 - 154
  • [22] CLINICAL STUDIES WITH LEVODOPA/CARBIDOPA INTESTINAL GEL
    Klivenyi Peter
    Vecsei Laszlo
    IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, 2014, 67 (1-2): : 5 - 8
  • [23] 24-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease
    Ricciardi, Lucia
    Bove, Francesco
    Espay, Kristy J.
    Lena, Francesco
    Modugno, Nicola
    Poon, Yu-Yan
    Krikorian, Robert
    Espay, Alberto J.
    Fasano, Alfonso
    MOVEMENT DISORDERS, 2016, 31 (04) : 597 - 598
  • [24] Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review
    Wirdefeldt, Karin
    Odin, Per
    Nyholm, Dag
    CNS DRUGS, 2016, 30 (05) : 381 - 404
  • [25] Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease
    Zibetti, M.
    Rizzone, M.
    Merola, A.
    Angrisano, S.
    Rizzi, L.
    Montanaro, E.
    Cicolin, A.
    Lopiano, L.
    ACTA NEUROLOGICA SCANDINAVICA, 2013, 127 (05): : e28 - e32
  • [26] Improvement of impulse control disorders associated with levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease
    Jose Catalan, Maria
    Antonio Molina-Arjona, Jose
    Mir, Pablo
    Cubo, Esther
    Matias Arbelo, Jose
    Martinez-Martin, Pablo
    JOURNAL OF NEUROLOGY, 2018, 265 (06) : 1279 - 1287
  • [27] Single-Center Study of 103 Consecutive Parkinson's Disease Patients with Levodopa-Carbidopa Intestinal Gel
    Viljaharju, Vili
    Mertsalmi, Tuomas
    Pauls, K. Amande M.
    Koivu, Maija
    Eerola-Rautio, Johanna
    Udd, Marianne
    Pekkonen, Eero
    MOVEMENT DISORDERS CLINICAL PRACTICE, 2022, 9 (01): : 60 - 68
  • [28] Transcutaneous port for levodopa/carbidopa intestinal gel administration in Parkinson's disease
    van Laar, T.
    Nyholm, D.
    Nyman, R.
    ACTA NEUROLOGICA SCANDINAVICA, 2016, 133 (03): : 208 - 215
  • [29] Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: long-term results from COSMOS
    Fasano, Alfonso
    Garcia-Ramos, Rocio
    Gurevich, Tanya
    Jech, Robert
    Bergmann, Lars
    Sanchez-Solino, Olga
    Parra, Juan Carlos
    Simu, Mihaela
    JOURNAL OF NEUROLOGY, 2023, 270 (05) : 2765 - 2775
  • [30] The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson's disease patients
    Antonini, Angelo
    Abbruzzese, Giovanni
    Berardelli, Alfredo
    Modugno, Nicola
    Stroppa, Italo
    Tamma, Filippo
    Sensi, Mariachiara
    Mancini, Francesca
    Cossu, Giovanni
    Stefani, Alessandro
    Tambasco, Nicola
    Tessitore, Alessandro
    Fabbrini, Giovanni
    Pontieri, Francesco E.
    Solla, Paolo
    Bentivoglio, Anna Rita
    Comi, Cristoforo
    Minafra, Brigida
    Riboldazzi, Giulio
    Melchionda, Donato
    Martino, Tommaso
    Lopiano, Leonardo
    JOURNAL OF NEURAL TRANSMISSION, 2020, 127 (06) : 881 - 891